Review



rh α gala  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    R&D Systems rh α gala
    FD patients’ cohort description. Activity of <t> α-GalA </t> (μmol/hL) was measured in dried blood spots (DBSs) at enrollment in the study. NT indicates non-treated FD patient. ERT = enzyme replacement therapy, PC = pharmacological chaperone. N.D. = not available, N.A. = not applicable.
    Rh α Gala, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+%CE%B1+gala/Recombinant+Human+alpha-Galactosidase+A%2FGLA+Protein%2C+CF/pmc11172779-258-5-7
    Average 93 stars, based on 10 article reviews
    rh α gala - by Bioz Stars, 2026-09
    93/100 stars

    Images

    1) Product Images from "Inflammatory and Cardiovascular Biomarkers to Monitor Fabry Disease Progression"

    Article Title: Inflammatory and Cardiovascular Biomarkers to Monitor Fabry Disease Progression

    Journal: International Journal of Molecular Sciences

    doi: 10.3390/ijms25116024

    FD patients’ cohort description. Activity of α-GalA (μmol/hL) was measured in dried blood spots (DBSs) at enrollment in the study. NT indicates non-treated FD patient. ERT = enzyme replacement therapy, PC = pharmacological chaperone. N.D. = not available, N.A. = not applicable.
    Figure Legend Snippet: FD patients’ cohort description. Activity of α-GalA (μmol/hL) was measured in dried blood spots (DBSs) at enrollment in the study. NT indicates non-treated FD patient. ERT = enzyme replacement therapy, PC = pharmacological chaperone. N.D. = not available, N.A. = not applicable.

    Techniques Used: Activity Assay, Mutagenesis

    Plasmatic activity levels. Histograms n panel ( A ) represent plasmatic α-GalA activity ± SEM (nmol/mL·h) in controls (white bars), FD naïve patients (light gray bars), and FD patients treated with ERT (white bars with dots). In panel ( B ), α-GalA activity values are separated according to sex. Significance was assessed by one-way ANOVA non-parametric test, Kruskal–Wallis multiple comparisons (* p < 0.05).
    Figure Legend Snippet: Plasmatic activity levels. Histograms n panel ( A ) represent plasmatic α-GalA activity ± SEM (nmol/mL·h) in controls (white bars), FD naïve patients (light gray bars), and FD patients treated with ERT (white bars with dots). In panel ( B ), α-GalA activity values are separated according to sex. Significance was assessed by one-way ANOVA non-parametric test, Kruskal–Wallis multiple comparisons (* p < 0.05).

    Techniques Used: Activity Assay

    Anti-α-GalA-IgG antibody concentration. Concentration of IgG antibodies determined by ELISA in plasma samples of control individuals and patients in treatment or not with ERT, collected at Ti, T6, T12 months. ( A ) Average values (mean ± SEM) for each group of patients at each collection time. ( B ) Individual values (mean of two replicates) for each subject of the study at all assessed times. ( C ) Time course of anti-α-GalA antibodies for the four patients in panel ( B ), who presented antibody levels close or above the threshold. In all graphs, dotted lines represent threshold.
    Figure Legend Snippet: Anti-α-GalA-IgG antibody concentration. Concentration of IgG antibodies determined by ELISA in plasma samples of control individuals and patients in treatment or not with ERT, collected at Ti, T6, T12 months. ( A ) Average values (mean ± SEM) for each group of patients at each collection time. ( B ) Individual values (mean of two replicates) for each subject of the study at all assessed times. ( C ) Time course of anti-α-GalA antibodies for the four patients in panel ( B ), who presented antibody levels close or above the threshold. In all graphs, dotted lines represent threshold.

    Techniques Used: Concentration Assay, Enzyme-linked Immunosorbent Assay, Clinical Proteomics, Control

    Related Articles

    Recombinant:

    Article Title: The New Pharmacological Chaperones PBXs Increase α-Galactosidase A Activity in Fabry Disease Cellular Models
    Article Snippet: Total protein concentration was measured with PierceTM BCA Protein Assay Kit (Thermo-Fisher, Thermofisher, Fair Lawn, NJ, USA) following the manufacturer’s instructions. .. Recombinant human α-GalA (#6146-GH, R&D Systems, Minneapolis, MN, USA) was pre-incubated at either 37 °C, 39 °C, or 42 °C for 15 min with different concentrations of PB48 (150, 75, 50, 20, 10, 5, 2, 0.5, 0 μM) in Phosphate-Citrate buffer 0.15 M (pH = 4.2) with HALT protease inhibitor. ..

    Article Title: Quantifying lysosomal glycosidase activity within cells using bis-acetal substrates.
    Article Snippet: 1Department of Chemistry, Simon Fraser University, Burnaby, British Columbia, Canada.. 2Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, British Columbia, Canada.. 3Present address: Department of Chemistry, Université de Montréal, Québec, Canada.

    Protease Inhibitor:

    Article Title: The New Pharmacological Chaperones PBXs Increase α-Galactosidase A Activity in Fabry Disease Cellular Models
    Article Snippet: Total protein concentration was measured with PierceTM BCA Protein Assay Kit (Thermo-Fisher, Thermofisher, Fair Lawn, NJ, USA) following the manufacturer’s instructions. .. Recombinant human α-GalA (#6146-GH, R&D Systems, Minneapolis, MN, USA) was pre-incubated at either 37 °C, 39 °C, or 42 °C for 15 min with different concentrations of PB48 (150, 75, 50, 20, 10, 5, 2, 0.5, 0 μM) in Phosphate-Citrate buffer 0.15 M (pH = 4.2) with HALT protease inhibitor. ..



    Similar Products

    rh α gala  (R&D Systems)
    93
    R&D Systems rh α gala
    FD patients’ cohort description. Activity of <t> α-GalA </t> (μmol/hL) was measured in dried blood spots (DBSs) at enrollment in the study. NT indicates non-treated FD patient. ERT = enzyme replacement therapy, PC = pharmacological chaperone. N.D. = not available, N.A. = not applicable.
    Rh α Gala, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+%CE%B1+gala/Recombinant+Human+alpha-Galactosidase+A%2FGLA+Protein%2C+CF/pmc11172779-258-5-7
    Average 93 stars, based on 1 article reviews
    rh α gala - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    recombinant human α gala  (R&D Systems)
    93
    R&D Systems recombinant human α gala
    FD patients’ cohort description. Activity of <t> α-GalA </t> (μmol/hL) was measured in dried blood spots (DBSs) at enrollment in the study. NT indicates non-treated FD patient. ERT = enzyme replacement therapy, PC = pharmacological chaperone. N.D. = not available, N.A. = not applicable.
    Recombinant Human α Gala, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+%CE%B1+gala/Recombinant+Human+IL-5+R+alpha+Protein/pm35210619-229-0-8
    Average 93 stars, based on 1 article reviews
    recombinant human α gala - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    FD patients’ cohort description. Activity of α-GalA (μmol/hL) was measured in dried blood spots (DBSs) at enrollment in the study. NT indicates non-treated FD patient. ERT = enzyme replacement therapy, PC = pharmacological chaperone. N.D. = not available, N.A. = not applicable.

    Journal: International Journal of Molecular Sciences

    Article Title: Inflammatory and Cardiovascular Biomarkers to Monitor Fabry Disease Progression

    doi: 10.3390/ijms25116024

    Figure Lengend Snippet: FD patients’ cohort description. Activity of α-GalA (μmol/hL) was measured in dried blood spots (DBSs) at enrollment in the study. NT indicates non-treated FD patient. ERT = enzyme replacement therapy, PC = pharmacological chaperone. N.D. = not available, N.A. = not applicable.

    Article Snippet: Briefly, plates were coated with rh-α-GalA (#6146-GH, R&D, Systems), which binds to IgG antibodies against the α-GalA recombinant enzyme (diluted 1:50 in PBS with 5% low fat milk).

    Techniques: Activity Assay, Mutagenesis

    Plasmatic activity levels. Histograms n panel ( A ) represent plasmatic α-GalA activity ± SEM (nmol/mL·h) in controls (white bars), FD naïve patients (light gray bars), and FD patients treated with ERT (white bars with dots). In panel ( B ), α-GalA activity values are separated according to sex. Significance was assessed by one-way ANOVA non-parametric test, Kruskal–Wallis multiple comparisons (* p < 0.05).

    Journal: International Journal of Molecular Sciences

    Article Title: Inflammatory and Cardiovascular Biomarkers to Monitor Fabry Disease Progression

    doi: 10.3390/ijms25116024

    Figure Lengend Snippet: Plasmatic activity levels. Histograms n panel ( A ) represent plasmatic α-GalA activity ± SEM (nmol/mL·h) in controls (white bars), FD naïve patients (light gray bars), and FD patients treated with ERT (white bars with dots). In panel ( B ), α-GalA activity values are separated according to sex. Significance was assessed by one-way ANOVA non-parametric test, Kruskal–Wallis multiple comparisons (* p < 0.05).

    Article Snippet: Briefly, plates were coated with rh-α-GalA (#6146-GH, R&D, Systems), which binds to IgG antibodies against the α-GalA recombinant enzyme (diluted 1:50 in PBS with 5% low fat milk).

    Techniques: Activity Assay

    Anti-α-GalA-IgG antibody concentration. Concentration of IgG antibodies determined by ELISA in plasma samples of control individuals and patients in treatment or not with ERT, collected at Ti, T6, T12 months. ( A ) Average values (mean ± SEM) for each group of patients at each collection time. ( B ) Individual values (mean of two replicates) for each subject of the study at all assessed times. ( C ) Time course of anti-α-GalA antibodies for the four patients in panel ( B ), who presented antibody levels close or above the threshold. In all graphs, dotted lines represent threshold.

    Journal: International Journal of Molecular Sciences

    Article Title: Inflammatory and Cardiovascular Biomarkers to Monitor Fabry Disease Progression

    doi: 10.3390/ijms25116024

    Figure Lengend Snippet: Anti-α-GalA-IgG antibody concentration. Concentration of IgG antibodies determined by ELISA in plasma samples of control individuals and patients in treatment or not with ERT, collected at Ti, T6, T12 months. ( A ) Average values (mean ± SEM) for each group of patients at each collection time. ( B ) Individual values (mean of two replicates) for each subject of the study at all assessed times. ( C ) Time course of anti-α-GalA antibodies for the four patients in panel ( B ), who presented antibody levels close or above the threshold. In all graphs, dotted lines represent threshold.

    Article Snippet: Briefly, plates were coated with rh-α-GalA (#6146-GH, R&D, Systems), which binds to IgG antibodies against the α-GalA recombinant enzyme (diluted 1:50 in PBS with 5% low fat milk).

    Techniques: Concentration Assay, Enzyme-linked Immunosorbent Assay, Clinical Proteomics, Control